drugset / Trial / NCT06557174
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2025-11-10
- Completion
- 2026-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMC-002 | Unknown | 0.8 mg/kg | Intravenous |
| Subject | IMC-002 | Unknown | 1.2 mg/kg | Intravenous |
| Comparator | Mycophenolate Mofetil | Small molecule | 0.2 g | Oral |